Systematic (IUPAC) name | |
---|---|
(1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one | |
Clinical data | |
Trade names | Aerobid |
AHFS/Drugs.com | monograph |
MedlinePlus | a681048 |
Pregnancy cat. | ? |
Legal status | ? |
Routes | Inhaled |
Pharmacokinetic data | |
Protein binding | 40% after oral inhalation |
Half-life | 1.8 hours |
Identifiers | |
CAS number | 3385-03-3 |
ATC code | R01AD04 R03BA03 |
PubChem | CID 82153 |
DrugBank | APRD00976 |
ChemSpider | 74144 |
UNII | 78M02AA8KF |
KEGG | D00324 |
ChEBI | CHEBI:5106 |
ChEMBL | CHEMBL1512 |
Synonyms | 6α-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione acetone cyclic 16,17-acetal |
Chemical data | |
Formula | C24H31FO6 |
Mol. mass | 434.498 g/mol |
SMILES | eMolecules & PubChem |
|
|
(verify) |
(what is this?)
Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid often prescribed as treatment for allergic rhinitis.
The principal mechanism of action of flunisolide is to activate glucocorticoid receptors, meaning it has an anti-inflammatory action.
|
|